A recent review article lists six other JAK inhibitors that might be used as treatments for vitiligo in addition to ruxolitinib, the active ingredient in recently approved Opzelura.
Dermatology Times, November 2022 (Vol. 43. No. 11)
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Derm Dispatch: What 'Free to Be Me' Means to Tori Spelling and Stella McDermott
3
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
4
Dermatology Conferences and Meetings Calendar: December 2025
5
